After exclusion of reactive processes, carcinomas, and mesenchymal neoplasms, additional EMA, desmin, IMP‐3, and thrombomodulin positivity can be observed in the majority of cases, alongside with BAP1 loss. This evidence concerns the gene THBD and mesenchymal cell neoplasm.